Last reviewed · How we verify

NCT03205306

Myasthenia Gravis and Psyche

Completed Last updated 10 January 2023
What this trial tests

trial in Myasthenia Gravis in 1,399 participants. Completed in 14 December 2017.

Timeline
8 May 2017
Primary endpoint
14 December 2017
14 December 2017

Quick facts

Lead sponsorCharite University, Berlin, Germany
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,399
Start date8 May 2017
Primary completion14 December 2017
Estimated completion14 December 2017
Sites1 location across Germany

Conditions studied

Sponsor

Charite University, Berlin, Germany

Who can join

18 and older, any sex, with Myasthenia Gravis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to systematically capture and characterize mental comorbidities for patients with myasthenia gravis. Anxiety disorders and depression for example, can negatively affect the quality of life and lead to e.g. unemployment and early retirement especially in young patients. Additionally the researchers want to find out in what way certain aspects of the disease have an influence on the quality of life, and whether different concepts of coping with the disease have different effects on the quality of life for patients with myasthenia gravis. During the study, close relatives of patients will also be asked to provide input about their current stress situation in the context of supporting their relative. Based on the results, the investigators want to improve and supplement established treatment concepts, to ensure a more comprehensive and individual treatment.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Understanding the burden of refractory myasthenia gravis.
    Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. · · 2019 · cited 123× · PMID 30854027 · DOI 10.1177/1756286419832242
  2. Burden of disease in myasthenia gravis: taking the patient's perspective.
    Lehnerer S, Jacobi J, Schilling R, Grittner U, et al · · 2022 · cited 114× · PMID 34800167 · DOI 10.1007/s00415-021-10891-1
  3. Mental health in myasthenia gravis patients and its impact on caregiver burden.
    Marbin D, Piper SK, Lehnerer S, Harms U, et al · · 2022 · cited 23× · PMID 36369246 · DOI 10.1038/s41598-022-22078-3

Verify or expand the search:

Other recruiting trials for Myasthenia Gravis

Currently open trials in the same condition.

Other Charite University, Berlin, Germany trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03205306.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing